drugset / Trial / NCT06580236
Study of the Drug B11-FC (Botulism Treatment)
Phase 1/2
Not yet recruiting
40 enrolled
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
RandomizedSequentialOpen-labelTreatment
Summary
Study of the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of the drug B11-FC with a single application in adults
Timeline
- Start
- 2024-08
- Primary completion
- 2025-03-30
- Completion
- 2025-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B11-FC | Monoclonal antibody | 0.06 mg/kg | Other |
| Subject | B11-FC | Monoclonal antibody | 0.3 mg/kg | Other |
| Subject | B11-FC | Monoclonal antibody | 0.6 mg/kg | Other |